The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
E Karran, B De Strooper - Nature Reviews Drug Discovery, 2022 - nature.com
Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring
Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
Four distinct trajectories of tau deposition identified in Alzheimer's disease
Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …
Alzheimer's disease
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic …
Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …